Dietary Supplement Industry Pushes for Expanded Ingredient Options
The Australian dietary supplement industry is lobbying the Food and Drug Administration (FDA) to broaden the scope of ingredients permitted in their products. This move could significantly increase the availability and marketing of popular wellness offerings such as peptides and probiotics. The FDA recently convened a public meeting to deliberate on its criteria for classifying dietary supplements and whether these definitions could be expanded to encompass substances not traditionally derived from food, vitamins, herbs, or other common sources. Industry leaders, consumer advocates, and academic experts are participating in these discussions.
This significant meeting is the first of its kind since Robert F. Kennedy Jr. took the helm as the nation’s top health official last year. Kennedy has publicly pledged to tackle the regulatory hurdles within the FDA concerning dietary supplements, peptides, and other products associated with his “Make America Healthy Again” initiative.
The push for this discussion was initiated by the Natural Products Association, an organisation that has previously clashed with the FDA over specific novel supplement ingredients. In a formal letter penned in January, the association underscored the considerable costs and uncertainties faced by the industry due to ambiguous regulatory expectations.
Navigating Current Regulations and Emerging Ingredients
Under the FDA’s existing regulations, dietary supplements are classified as a type of food. This classification typically means that the majority of their ingredients must be sourced from plants, herbs, and other substances commonly found in the typical Australian diet. This stringent requirement has presented a significant hurdle for the industry, particularly as newer wellness products frequently incorporate ingredients that have not historically been part of the food supply.
A prime example of this evolving landscape is peptides. These are chains of amino acids that have been heavily promoted by celebrities and social media influencers, often lauded for their purported benefits in muscle building and anti-aging. Despite widespread claims, robust scientific evidence to substantiate these assertions remains limited. While many specialised pharmacies and clinics offer peptides through injections or intravenous infusions, an increasing number of supplement manufacturers are now embedding these compounds into capsules, gummies, and powders.
According to FDA legal counsel, such products currently contravene existing FDA regulations. This also extends to certain types of probiotics, which are widely marketed for their digestive and gut health benefits. Industry representatives, however, contend that current legislation does not explicitly mandate that all supplement ingredients must exclusively originate from food sources.
Robert Durkin, a former official within the FDA’s supplements program and now a consultant for various companies, expressed a degree of optimism. He stated, “The hope of the meeting is that FDA is willing to open up its interpretation of what constitutes a dietary ingredient to allow dietary substances that aren’t already in food.”
The Threat of Legal Action and Kennedy’s Stance
Should the FDA refrain from redefining the term “dietary ingredient,” the industry may explore legal avenues. This possibility is amplified by a Supreme Court ruling in 2024 that curtailed the authority of federal regulators to interpret laws and establish comprehensive regulations.
Robert F. Kennedy Jr. has been an outspoken advocate for peptides, describing himself as “a big fan” during a podcast with Joe Rogan. He also shared his personal use of them for injury treatment. His stated aim is to reduce FDA restrictions on the production of injectable peptides, which have historically been subject to federal safety regulations.
Several of Kennedy’s prominent supporters are actively involved in marketing peptide-based products. Gary Brecka, who identifies as a “longevity expert,” promotes peptide injectables, patches, and nasal sprays. Dr. Mark Hyman, another associate of Kennedy, markets a range of dietary supplements, including those containing peptides, through his own platform.
Further connections to the supplement industry are evident in the former health advisors of Kennedy’s presidential campaign. Calley Means, currently a senior advisor within the Department of Health and Human Services, co-founded a platform that empowers consumers to utilise tax-free health dollars for the purchase of wellness products. His sister, Dr. Casey Means, who was nominated by former President Donald Trump to be the Surgeon General, has reportedly amassed significant income through promoting supplements and probiotics.
The FDA’s Regulatory Approach to Supplements
It is important to note that the FDA does not regulate dietary supplements with the same level of stringent oversight applied to pharmaceuticals and other medical products. The agency does not maintain an exhaustive registry of all supplements available on the market. With an estimated 100,000 supplements currently in circulation, the onus falls upon manufacturers to ensure the safety and accuracy of their product marketing. Crucially, supplements are prohibited from making claims to treat specific diseases or medical conditions.
The 1994 legislation that granted the FDA oversight of the supplement industry effectively exempted manufacturers from stringent nutrition labelling requirements, which would otherwise necessitate scientific substantiation for health claims. Instead, supplement producers are permitted to make broader, more general assertions about maintaining or supporting overall health.
Some former regulators have voiced concerns that this regulatory framework has inherent flaws. Mitch Zeller, who was involved in supplement regulations at the FDA during the 1990s, commented, “It sanctioned unauthorized, implied health claims.” He highlighted that many claims featured on supplement labels or in advertisements are meticulously worded to circumvent classification as drug claims.
Companies are also permitted to assert that their products enhance the structure or function of particular body parts, such as improving bone strength. However, any product making such claims must prominently display a disclaimer stating, “This statement has not been evaluated by the FDA.” This distinction is critical for consumers to understand the regulatory standing of these products compared to conventional medicines.
